Blood cancers · 2024–25 results
Multiplex-edited CAR-T inducing remissions
Early clinical studies show that cells carrying multiple base edits can induce remissions.
Chiesa et al., NEJMStarting with recurrent glioblastoma
Programmable
durabilityfor solid-tumor cell therapy.
We engineer healthy-donor CAR-T cells to resist the signals tumors use to shut them down.
KGEN-001 · Preclinical development
Explore Our Science
KGEN-001 · Lead program
Engineered to make control last in glioblastoma.
KGEN-001 starts with healthy-donor cells. Engineered to resist multiple GBM suppression pathways.
Explore KGEN-001KGEN-001 is in preclinical development.
CAR-T therapies use engineered immune cells to recognize and attack cancer.
The durability gap
In recurrent glioblastoma, CAR-T can shrink tumors. Control often does not last.
Published GBM CAR-T example Not KGEN-001
Before treatment
3 days after CAR-T
Patient 26 · Disease progressed by month 1
8 of 13 Patients with measurable tumors showed shrinkage on imagingRadiographic regression 1.9 months Median progression-free survivaln=18 · Time until disease progression or death
Why now
We now have the tools and evidence to engineer durable brain-tumor CAR-T.
Recurrent GBM · 2025
Off-the-shelf CAR-T cleared for Phase 2
T-Maximum announced FDA clearance for a Phase 2 trial of donor-derived CAR-T in recurrent GBM.
T-Maximum announcementHuman GBM · 2026
Immune suppression linked to outcomes
Human studies link suppressive immune-cell populations to poorer CAR-T responses.
Freeburg et al., CellPatient evidence guides what we protect against. Multiplex editing lets us combine those protections in one CAR-T cell.
External clinical and biological precedents, not KGEN-001 results. Early T-ALL/T-LL studies; nine BE-CAR7 responders proceeded to stem-cell transplantation.
KiraGen’s approach
Noise cancellation for cell therapy.
We build CAR-T cells to ignore multiple signals, not overpower them.
Combinations of coordinated gene edits. Designed to resist multiple tumor shutdown signals.Explore our approachWhy this team
From multiplex design to patient dosing,
we have done it before.
Members of our team have helped advance multiplex base-edited CAR-T cells from research into clinical development.
The vision
Programmable
durability.
KGEN-001 is our first design.
KiraLOGIC prioritizes what we build and test next.
Ready when patients need them.
Built to endure when tumors fight back.
Backed by investors. Supported by disease foundations.
Investor backing
Disease foundation support
